Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03686683 · ClinicalTrials.gov registry record · Phase 3
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
A Phase 3 study, sponsored by Dendreon.
- Completed
- Registry status
- Phase 3
- Development phase
- 532
- Enrollment target
NCT03686683 is a Phase 3 study that has completed, run by Dendreon. The registered enrollment target is 532 participants.
The verdict
NCT03686683, a Phase 3 study, has completed, sponsored by Dendreon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 532 participants
- Enrollment target
Study Summary
The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-metastatic prostate cancer compared to participants followed on active surveillance as standard of care.
Interventions
- BIOLOGICAL sipuleucel-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 532 participants |
| Start Date | 2018-10-18 |
| Est. Completion | 2023-03-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03686683
The ClinicalTrials.gov registry entry for NCT03686683 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 532 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dendreon, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sipuleucel-T is the first listed.
NCT03686683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03686683 about?
NCT03686683 is a clinical study titled "Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer". The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-metastatic prostate cancer compared to participants followed on active surveillance as standard of care.
What is the current status of trial NCT03686683?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 532 participants. The study started on 2018-10-18. Estimated completion is 2023-03-10.
What interventions are being tested in trial NCT03686683?
The interventions under investigation include: sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT03686683?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.